Assoc. Prof. DENİZ CAN GÜVEN

Journal of clinical oncology : official journal of the American Society of Clinical Oncology , vol.41, no.30, pp.4821-4822, 2023 (SCI-Expanded, Scopus)

71. Comparison of Adjuvant Modified FOLFIRINOX with Other Adjuvant Chemotherapies in Resected Pancreatic Adenocarcinoma: Real-life Data

EROL C., HAFIZOĞLU E., aykan m. b., GÜVEN D. C., Dursun B., Hizal M., et al.

ACTA ONCOLOGICA TURCICA , vol.56, no.2, pp.170-179, 2023 (TRDizin)

72. Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer

Şener G. Y., SÜTCÜOĞLU O., ÖĞÜT B., GÜVEN D. C., KAVUNCUOĞLU A., ÖZDEMİR N., et al.

Strahlentherapie und Onkologie , vol.199, no.8, pp.761-772, 2023 (SCI-Expanded, Scopus)

73. Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectives

ERUL E., GÜVEN D. C., ONUR M. R., YAZICI G., AKSOY S.

European Archives of Oto-Rhino-Laryngology , vol.280, no.8, pp.3541-3556, 2023 (SCI-Expanded, Scopus)

74. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Hizal M., Bilgin B., Paksoy N., Atci M. M., KAHRAMAN S., Kilickap S., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.149, no.8, pp.4141-4148, 2023 (SCI-Expanded, Scopus)

75. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.

Anti-Cancer Drugs , vol.34, no.6, pp.783-790, 2023 (SCI-Expanded, Scopus)

76. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study

GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.149, no.7, pp.3599-3606, 2023 (SCI-Expanded, Scopus)

77. SMART syndrome: a case report

Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., et al.

ACTA NEUROLOGICA BELGICA , vol.123, no.3, pp.1137-1140, 2023 (SCI-Expanded, Scopus)

78. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort

AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.

Medicine (United States) , vol.102, no.18, 2023 (SCI-Expanded, Scopus)

79. Learning From Failure: Negative Trials in Oncology

Nardo M., GÜVEN D. C., Yikilmaz A. S., Singh S., Ahmed J.

Journal of Immunotherapy and Precision Oncology , vol.6, no.2, pp.59-60, 2023 (Scopus)

80. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma

GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., et al.

European Archives of Oto-Rhino-Laryngology , vol.280, no.5, pp.2471-2478, 2023 (SCI-Expanded, Scopus)

81. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer

Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., et al.

Clinics and Research in Hepatology and Gastroenterology , vol.47, no.3, 2023 (SCI-Expanded, Scopus) Sustainable Development

82. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Kahraman S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., et al.

Future oncology (London, England) , vol.19, no.10, pp.727-736, 2023 (SCI-Expanded, Scopus)

83. Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer

Akagunduz B., Guven D. C., Ozer M., Okten I. N., Atag E., Unek İ. T., et al.

Journal of Geriatric Oncology , vol.14, no.2, 2023 (SCI-Expanded, Scopus) Sustainable Development

84. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.

INTERNATIONAL JOURNAL OF CANCER , vol.152, pp.679-685, 2023 (SCI-Expanded, Scopus)

85. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.

Journal of Oncological Science , vol.9, no.1, pp.33-37, 2023 (Scopus, TRDizin)

86. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment

Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.

Expert Review of Anticancer Therapy , vol.23, no.10, pp.1049-1059, 2023 (SCI-Expanded, Scopus)

87. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Erol C., Bardakçi M., Hizal M., Kahraman S., Yekedüz E., GÜVEN D. C., et al.

Journal of Oncological Science , vol.9, no.2, pp.72-78, 2023 (Scopus, TRDizin)

88. Emerging treatment strategies in hepatobiliary cancer

GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.

Expert Review of Anticancer Therapy , vol.23, no.3, pp.243-256, 2023 (SCI-Expanded, Scopus) Sustainable Development

89. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

GÜVEN D. C., ŞAHİN T. K., ERUL E., Rizzo A., Ricci A. D., AKSOY S., et al.

Frontiers in Molecular Biosciences , vol.9, 2022 (SCI-Expanded, Scopus)

90. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.

BREAST , vol.66, pp.85-88, 2022 (SCI-Expanded, Scopus)

91. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Gurbuz M., Kutlu Y., AKKUŞ E., KÖKSOY E. B., Kose N., Oven B. B., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.12, pp.3547-3555, 2022 (SCI-Expanded, Scopus) Sustainable Development

92. Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review

YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., et al.

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY , vol.15, no.4, pp.307-310, 2022 (ESCI, Scopus)

93. Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards

GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.8, pp.1807-1811, 2022 (SCI-Expanded, Scopus) Sustainable Development

94. Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine

Carloni R., Rizzo A., Ricci A. D., Di Federico A., De Luca R., GÜVEN D. C., et al.

TRANSLATIONAL ONCOLOGY , vol.25, 2022 (SCI-Expanded, Scopus)

95. SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research

GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.

ONCOLOGIST , vol.27, no.11, 2022 (SCI-Expanded, Scopus) Sustainable Development

96. Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis

BAŞ O., Erul E., GÜVEN D. C., AKSOY S.

SUPPORTIVE CARE IN CANCER , vol.30, no.11, pp.9071-9078, 2022 (SCI-Expanded, Scopus)

97. The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges

GÜVEN D. C., ŞAHİN T. K., Rizzo A., Ricci A. D., AKSOY S., ŞAHİN K.

APPLIED SCIENCES-BASEL , vol.12, no.20, 2022 (SCI-Expanded, Scopus)

98. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

JOURNAL OF CLINICAL MEDICINE , vol.11, no.17, 2022 (SCI-Expanded, Scopus)

99. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.

JOURNAL OF CLINICAL MEDICINE , vol.11, no.15, 2022 (SCI-Expanded, Scopus)

100. Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report

TABAN H., GÜVEN D. C., Kilickap S.

CUREUS JOURNAL OF MEDICAL SCIENCE , vol.14, no.8, 2022 (ESCI)

101. Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis

Rizzo A., Carloni R., Ricci A. D., Di Federico A., GÜVEN D. C., YALÇIN Ş., et al.

JOURNAL OF PERSONALIZED MEDICINE , vol.12, no.8, 2022 (SCI-Expanded, Scopus)

102. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Hizal M., Bilgin B., Paksoy N., Acikgoz O., Sezer A., Gurbuz M., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.6, pp.1501-1508, 2022 (SCI-Expanded, Scopus)

103. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy

GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.4, pp.785-793, 2022 (SCI-Expanded, Scopus) Sustainable Development

104. Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.

Guven D. C., Sayegh N., Tripathi N., Erman M., Agarwal N., Swami U.

JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16, 2022 (SCI-Expanded, Scopus)

105. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

GÜVEN D. C., ŞAHİN T. K., Erul E., KILIÇKAP S., Gambichler T., AKSOY S.

CANCERS , vol.14, no.11, 2022 (SCI-Expanded, Scopus)

106. Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

Gurbuz M., Akkus E., Sakin A., Urvay S., Demiray A. G., Sahin S., et al.

JOURNAL OF GASTROINTESTINAL CANCER , vol.53, no.2, pp.282-288, 2022 (ESCI, Scopus) Sustainable Development

107. The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials

GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., Erul E., AKSOY S.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , vol.174, 2022 (SCI-Expanded, Scopus)

108. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination

GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.

ONCOLOGIST , vol.27, 2022 (SCI-Expanded, Scopus)

109. HER2-low breast cancer could be associated with an increased risk of brain metastasis

GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.27, no.2, pp.332-339, 2022 (SCI-Expanded, Scopus) Sustainable Development

110. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.52, no.5, pp.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin)

111. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , vol.6, no.1, pp.59-63, 2022 (ESCI, TRDizin) Sustainable Development

112. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.

FUTURE ONCOLOGY , vol.18, pp.323-331, 2022 (SCI-Expanded, Scopus) Sustainable Development

113. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment

GÜRLER F., Ilhan A., GÜVEN D. C., TURHAN O., KURT İNCİ B., SÜTCÜOĞLU O., et al.

ANTI-CANCER DRUGS , vol.33, no.1, 2022 (SCI-Expanded, Scopus)

114. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.

Journal of Oncological Science , vol.8, no.3, pp.143-147, 2022 (Scopus, TRDizin)

115. Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma

Gurler F., GÜVEN D. C., Aydemir E., SÜTCÜOĞLU O., Inci B. K., ARIK Z., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.52, no.5, pp.1559-1568, 2022 (SCI-Expanded, Scopus, TRDizin)

116. Thirty-day mortality rates after immunotherapy initiation

SÜTCÜOĞLU O., Ilhan A., Tacar S. Y., GÜVEN D. C., Ucar G., Karadurmus N., et al.

IMMUNOTHERAPY , vol.13, pp.1419-1426, 2021 (SCI-Expanded, Scopus)

117. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study

GÜVEN D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., et al.

CURRENT PROBLEMS IN CANCER , vol.45, no.6, 2021 (SCI-Expanded, Scopus)

118. Assessment of abuse and related factors in older patients with cancer

Akagunduz B., Altin Z., Atci M. M., Ozer M., GÜVEN D. C., Cil I., et al.

SUPPORTIVE CARE IN CANCER , vol.29, no.12, pp.7957-7964, 2021 (SCI-Expanded, Scopus) Sustainable Development

119. Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats

AKTEPE O. H., ŞAHİN T. K., GÜNER G., GÜVEN D. C., YETER H. H., KURTULAN O., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.32, no.12, pp.1049-1056, 2021 (SCI-Expanded, Scopus, TRDizin) Sustainable Development

120. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , vol.168, 2021 (SCI-Expanded, Scopus) Sustainable Development

121. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review

GÜVEN D. C., ŞAHİN T. K., KILIÇKAP S., Uckun F. M.

FRONTIERS IN ONCOLOGY , vol.11, 2021 (SCI-Expanded, Scopus)

122. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme

GÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N.

FUTURE ONCOLOGY , vol.17, pp.4405-4413, 2021 (SCI-Expanded, Scopus) Sustainable Development

123. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy

AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEN B., Yeter H. H., et al.

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL , vol.73, no.10, pp.1957-1963, 2021 (SCI-Expanded, Scopus)

124. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus)

125. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.

SUPPORTIVE CARE IN CANCER , vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded, Scopus) Sustainable Development

126. Sarcopenia and anthracycline cardiotoxicity in patients with cancer

BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus) Sustainable Development

127. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.

BIOMARKERS IN MEDICINE , vol.15, no.13, pp.1123-1130, 2021 (SCI-Expanded, Scopus) Sustainable Development

128. Neoadjuvant capecitabine in rectal cancer chemoradiotherapy: too early to ring the alarms

GÜVEN D. C., YALÇIN Ş.

INTERNAL MEDICINE JOURNAL , vol.51, no.8, pp.1365-1366, 2021 (SCI-Expanded, Scopus) Sustainable Development

129. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report

GÜVEN D. C., KILIÇKAP S., YILDIRIM H. Ç., Ceylan F., BAŞ O., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.27, no.5, pp.1281-1283, 2021 (SCI-Expanded, Scopus)

130. Reassurance of patients with cancer on cancer care continuum: a vital strategy to prevent anxiety of COVID-19 collateral damage

GÜVEN D. C.

SUPPORTIVE CARE IN CANCER , vol.29, pp.3423-3424, 2021 (SCI-Expanded, Scopus)

131. A novel agnostic tumor: NTRKoma

Ayasun R., GÜVEN D. C., Gullu İ. H.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.27, no.4, pp.802-803, 2021 (SCI-Expanded, Scopus)

132. Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review

Yigit E., GÜVEN D. C., AKSOY S., YAZICI G.

CUREUS , vol.13, no.6, 2021 (ESCI)

133. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , vol.36, 2021 (SCI-Expanded, Scopus)

134. Artificial intelligence method to predict overall survival of hepatocellular carcinoma

ŞİMŞEK C., GÜVEN D. C., Sahin T. K., TEKİN İ. E., Sahan O., BALABAN H. Y., et al.

Hepatology Forum , vol.2, no.2, pp.64-68, 2021 (Scopus)

135. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al.

SUPPORTIVE CARE IN CANCER , vol.29, no.4, pp.2029-2035, 2021 (SCI-Expanded, Scopus) Sustainable Development

136. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer

Turker S., Cilbir E., GÜVEN D. C., Karacin C., YALÇIN Ş.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.17, no.2, pp.510-515, 2021 (SCI-Expanded, Scopus) Sustainable Development

137. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma

AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., et al.

TURKISH JOURNAL OF UROLOGY , vol.47, no.2, pp.113-119, 2021 (ESCI, Scopus, TRDizin)

138. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.

CANCER RESEARCH , vol.81, no.4, 2021 (SCI-Expanded, Scopus) Sustainable Development

139. Thyroid gland metastasis mimicking thyroid carcinoma in a lung cancer patient and dramatic response to crizotinib: A case report

Erul E., GÜVEN D. C., ŞAHİN T. K., Gullu İ. H.

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX , vol.69, no.1, pp.98-101, 2021 (ESCI, Scopus, TRDizin)

140. The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters

GÜVEN D. C., ŞAHİN T. K., AKSOY S.

BREAST JOURNAL , vol.26, no.12, pp.2435-2436, 2020 (SCI-Expanded, Scopus) Sustainable Development

141. Cancer incidence in Behcet's disease

GÜVEN D. C., BÖLEK E. Ç., ALTINTOP S. E., ÇELİKTEN B., AKTAŞ B. Y., KİRAZ S., et al.

IRISH JOURNAL OF MEDICAL SCIENCE , vol.189, no.4, pp.1209-1214, 2020 (SCI-Expanded, Scopus) Sustainable Development

142. Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)

Alkan A., Yasar A., Guc Z. G., Gurbuz M., BAŞOĞLU TÜYLÜ T., SEZGİN GÖKSU S., et al.

EUROPEAN JOURNAL OF CANCER CARE , vol.29, no.6, 2020 (SCI-Expanded, SSCI, Scopus) Sustainable Development

143. Effects of adenosine triphosphate on vandetanib induced skin damage in rats

Akagunduz B., ÖZÇİÇEK F., Kara A. V., GÜVEN D. C., YAZICI G. N., Coban A., et al.

CUTANEOUS AND OCULAR TOXICOLOGY , vol.39, no.4, pp.323-327, 2020 (SCI-Expanded, Scopus)

144. All Positives May Not Be the Same in Pancreatic Cancer Lessons Learned From the Past

Ceylan F., GÜVEN D. C., ŞAHİN T. K., ÖZBEK D. A., DİZDAR Ö.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , vol.43, no.9, pp.676, 2020 (SCI-Expanded, Scopus) Sustainable Development

145. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design

GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.

CLINICAL COLORECTAL CANCER , vol.19, no.3, 2020 (SCI-Expanded, Scopus) Sustainable Development

146. Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19

GÜVEN D. C., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., AKSOY S., KILIÇKAP S.

FRONTIERS IN ONCOLOGY , vol.10, 2020 (SCI-Expanded, Scopus)

147. Cancer incidence in Behcet's Disease.

Guven D. C., Bolek E. C., Altintop S. E., Celikten B., Aktas B. Y., Kiraz S., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020 (SCI-Expanded, Scopus)

148. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient

KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.2, pp.496-499, 2020 (SCI-Expanded, Scopus)

149. Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications

GÜVEN D. C., AKTAŞ B. Y., ŞİMŞEK C., AKSOY S.

FUTURE ONCOLOGY , vol.16, no.9, pp.497-506, 2020 (SCI-Expanded, Scopus)

150. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer

GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.1, pp.256-258, 2020 (SCI-Expanded, Scopus) Sustainable Development

151. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study

Sunar V., Korkmaz V., AKIN S., GÜVEN D. C., ARIK Z., Ates O., et al.

JOURNAL OF BUON , vol.24, no.6, pp.2327-2332, 2019 (SCI-Expanded, Scopus)

152. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy

AKTAŞ B. Y., Guner G., Guven D. C., Arslan C., DİZDAR Ö.

EXPERT REVIEW OF ANTICANCER THERAPY , vol.19, no.7, pp.589-601, 2019 (SCI-Expanded, Scopus) Sustainable Development

153. Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia

BİLGİN E., DİZDAR Ö., Guven D. C., Ceylan S., AYBI Ö., FIRLATAN B., et al.

Rheumatology International , vol.39, no.6, pp.1045-1051, 2019 (SCI-Expanded, Scopus) Sustainable Development

154. Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients

Guven D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.

BIOMARKERS IN MEDICINE , vol.13, no.9, pp.725-735, 2019 (SCI-Expanded, Scopus) Sustainable Development

155. Evaluation of cancer risk in patients with periodontal diseases

Guven D. C., DİZDAR Ö., AKMAN A. C., Berker E., Yekeduz E., Ceylan F., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.49, no.3, pp.826-831, 2019 (SCI-Expanded, Scopus, TRDizin)

156. A rare cause of proximal muscle weakness: immune necrotising myopathy

GÜVEN D. C., ERDEN A., KILIÇ L., ERDEM ÖZDAMAR S., KARADAĞ Ö.

SCOTTISH MEDICAL JOURNAL , vol.63, no.3, pp.82-86, 2018 (SCI-Expanded, Scopus)

157. Fusobacterium and colorectal carcinogenesis

Guven D. C., DİZDAR Ö.

CARCINOGENESIS , vol.39, no.1, pp.84, 2018 (SCI-Expanded, Scopus)

158. Increased cancer risk in patients with periodontitis

DİZDAR Ö., HAYRAN M., Guven D. C., YILMAZ T. B., TAHERI S., AKMAN A. C., et al.

CURRENT MEDICAL RESEARCH AND OPINION , vol.33, no.12, pp.2195-2200, 2017 (SCI-Expanded, Scopus) Sustainable Development

159. An Unusual Case of Tuberculosis Lenfadenitis Mimicking Tularemia

Başpınar B., HELVACI Ö., GÜVEN D. C., İNKAYA A. Ç.

Turkiye Klinikleri Journal of Internal Medicine , vol.1, no.2, pp.111-113, 2016 (Peer-Reviewed Journal)

160. Prognostic Factors In Breast Cancer Patients With Hepatic Metastases: Impact Of Molecular Subtype And Local Hepatic Treatment

ATEŞ Ö., GÜVEN D. C., BABACAN T., Sunar V., Sarici F., AKSOY S., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.4, pp.206-214, 2016 (SCI-Expanded, Scopus, TRDizin)

161. Fatigue May be Independently Active at a Certain Part of Spondyloarthritis Patients: Hur-BIO Real Life Results

KALYONCU U., Erden A., KILIÇ L., Seyhoglu E., Guven D. C., AKTAŞ B. Y., et al.

ARTHRITIS & RHEUMATOLOGY , vol.67, 2015 (SCI-Expanded, Scopus)

162. Acute erythroid leukemia in a patient with chronic lymphocytic leukemia

GÜVEN D. C., BABACAN T., Sarici F., AKIN S., Altundag K., Turker A.

JOURNAL OF BUON , vol.19, no.4, pp.1127, 2014 (SCI-Expanded, Scopus)

Papers Presented at Peer-Reviewed Scientific Conferences 11

1. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).

Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.

Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024, (Summary Text)

2. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

GÜVEN D. C., Incesu F. G. G., Yildirim H. C., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.

Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 September 2022, vol.33, (Summary Text)

3. outcomes of patients with resected pancreatic ductal adenocarcinoma

ceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., et al.

9th international gastrointestinal cancer conference, 6 - 08 December 2019, (Full Text)

4. MAY CANCER RISK BE DECREASED IN A LARGE COHORT OF CHILD AND ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS?

BİLGİN E., GÜVEN D. C., Ceylan S., AYBI ÖZDEMİR Ö., KARDAŞ R. C., FIRLATAN B., et al.

Annual European Congress of Rheumatology (EULAR), Madrid, Spain, 12 - 15 June 2019, vol.78, pp.993, (Summary Text)

5. Clinical features and prognosis of patients with liposarcoma: Single-center experience.

Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text)

6. Metastatic Choroidal Melanoma: Single Center Experience

AKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., et al.

2. Ulusal İmmunoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018, pp.1-48, (Full Text)

7. Kolorektal Kanserde 16S rDNA Sekanslama ile Oral Mikrobiyom Analizi

GÜVEN D. C., ERGÜNAY K., BRİNKMANN A., ALP A., AKDOĞAN KITTANA F. N., AKYÖN YILMAZ Y., et al.

2. Ulusal immünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018, (Full Text) Sustainable Development

8. Analysis of Fusobacterium nucleatum, Streptococcus gallolyticus and Porphyromonas gingivalis in saliva in colorektal patients and healty controls. Abst ID:”e15117”

GÜVEN D. C., DİZDAR Ö., ALP A., Akdoğan Kittana F. N., KARAKOÇ D., Hamaloğlu E., et al.

2018 ASCO, Chicago, United States Of America, 1 - 05 June 2018, (Summary Text)

9. Evaluation of cancer risk in patients with periodontal diseases.

GÜVEN D. C., DİZDAR Ö., AKMAN A. C., BERKER A. E., YEKEDÜZ E., CEYLAN F., et al.

2018 ASCO Annual Meeting, Chicago, United States Of America, 1 - 05 June 2018, vol.36, pp.13571, (Summary Text)

10. Kolorektal Kanserli Hastalarda Ve Sağlıklı Kontrollerde Tükürükte Fusobacterium Nucleatum, Streptococcus Gallolyticus Ve Porphyromonas Gingivalis Analizi

GÜVEN D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.

7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, (Summary Text) Sustainable Development

11. SEVERE PERIODONTITIS IS ASSOCIATED WITH INCREASED CANCER RISK

DİZDAR Ö., HAYRAN K. M., GÜVEN D. C., Yılmaz T. B., Taheri S., AKMAN A. C., et al.

GAP 2017 Conference, Texas, United States Of America, 9 - 11 May 2017, (Summary Text) Sustainable Development

Books 1

1. PATOFİZYOLOJİNİN TEMELLERİ

DURUSU TANRIÖVER M., SARI A., EŞME M., KOÇ YILDIRIM S., YILDIRIM M. Ş., BÖLEK E. Ç., et al.

PALME YAYINCILIK, 2017

Metrics

Publication

174

Publication (WoS)

158

Publication (Scopus)

151

Citation (WoS)

298

H-Index (WoS)

Citation (Scopus)

1050

H-Index (Scopus)

Citation (TrDizin)

H-Index (TrDizin)

Citation (Sum Other)

Open Access

UN Sustainable Development Goals

Publications & Works